Introduction
Nephropathic Cystinosis is a rare genetic disease characterised primarily by extremely high intracellular levels of the amino acid cystine, electrolyte imbalance, proximal renal tubular dysfunction (Fanconi syndrome) and general failure to thrive (1, 2) . The accumulation of cystine as crystals in most tissues leads to the progressive dysfunction of multiple organs (3) . The incidence of cystinosis is one in 100,000 -200,000 live births, and affects approximately 2000 patients in the world, although there are believed to be many more cases undiagnosed (2, 4) . Some infants will die due to dehydration and electrolyte imbalance from Fanconi syndrome without diagnosis (5) . In the US alone there are 500-600 reported cases, with between 20 and 40 born each year (5).
Cystinosis is categorised as a Lysosomal Storage Disorder (LSD), which is a group of progressive disorders that share multi-organ failure as an endpoint (3, 5) . As with all LSDs, no signs of abnormality are displayed at birth; the first symptoms of glomerular dysfunction begin to appear at around 6-12 months of age (2) . Without treatment most children will reach end-stage renal failure by age nine (5) , and grow at 50-60% of the expected rate. By the age of eight an untreated child with cystinosis will be the height of a 4-year old (5), and, if inadequately treated, may not reach four feet in height.
The condition is caused by a defect in the CTNS gene. This is gene codes for a 367 aminoacid lysosomal transport protein called Cystinosin. In healthy cells, the amino acid cystine is transported into the cytoplasm of the cell for processing. In cystinosis however, it accumulates within the lysosomes to levels of 10-1000 times those seen in healthy cells, whereupon it crystallises from solution, causing cell death and organ failure (6) . This crystallisation is widespread throughout the majority of the tissues and organs in the body (7) . If left untreated symptomatic deterioration leads to death by the second decade of life (8) .
The treatment for cystinosis involves the administration of the amino thiol cysteamine, which is used therapeutically in the bitartrate form as Cystagon TM . With early and diligent therapy, cystinosis patients can prevent or delay most of the non-renal complications and extend their lives into a fourth or fifth decade, live independently and some women have borne children (5, 9) . The renal damage is continuous however, and decline is inevitable (5) .
Cysteamine causes a range of side effects, and this is largely due to the high dose which is required as much of the drug is lost to first-pass metabolism (9) . High blood levels must be achieved, as a large proportion of the administered drug will bind to circulating proteins, and cannot be up taken by the cells (10, 11) . Patients should aim to take their dose at regular 6-hour intervals for the treatment to work effectively, as the plasma half-life of cysteamine is 1.88 hours (7), with blood levels peaking at 1h, and rapidly declining thereafter (5). This is a lifelong commitment and requires the patient to wake in the middle of the night (9) .
The drug has a foul taste and smell akin to rotten eggs, which regularly induces vomiting after ingestion (9) . In approximately 10-15% of patients this can be severe enough to halt therapy (5). Cysteamine and its metabolites are excreted in breath and sweat, and this is also an issue, especially when the child enters education. Cysteamine has the potential to cause potentially serious stomach irritations such as gastric acid hypersecretion, reverse peristalsis and bile reflux, and 97% of patients report gastrointestinal symptoms (12, 13) , which in many patients is severe enough to significantly limit therapy (14, 15, 16) .
Compliance can therefore be a major barrier to effective treatment, and lead to significant morbidity.
The rectal route of administration can largely avoid the phenomenon of first-pass effect.
This results from one of the three rectal veins draining into the hepatic system, while the middle and lower veins bypass this and drain directly into the systemic circulation. If the suppository is positioned correctly, the drug should not be subjected to the first pass effect.
This potentially allows a smaller dose to be administered, thereby reducing or eliminating some of the unpleasant side effects. They may also be beneficial for treating conditions in infancy, when capsules are difficult to administer, or when the oral route is compromised.
Rectal formulations are useful tools, particularly in a case such as this where the taste and side effects renders the task of swallowing a tablet very unpleasant and foreboding
Aims
Formulation science may provide a way to improve the current medication, significantly improving the lives of sufferers and those who care for them. By eliminating the taste and frequency of administration through alternative dosage forms, ease of administration of cysteamine could be improved. The aim of this work was to develop alternative formulations of cysteamine which could reduce or eliminate some of the side effects experienced using the current oral capsule, thereby improving the quality of life for those affected. An improvement in the ease of administration of cysteamine to infants and young children was a central objective, therefore suppositories were investigated. By avoiding the first-pass metabolism of cysteamine, a lower dose should be achievable, while the taste and upper-gastric side effects should be eliminated. A study conducted by Van't Hoff and co-workers was previously undertaken where a cysteamine-loaded suppository gel, for use in cystinosis, was evaluated. However this rectal formulation was eliminated before cysteamine absorption was completed (17).
Materials and methods

Materials
Cysteamine hydrochloride and polyethylene glycol grades 400, 600, 1000, 1500, 3000, 4000, 6000, 8000 and 14000 were obtained from Sigma. Witepsol W35 was obtained from Gattefosse (St-Priest, France). Gelucire 39/01 was purchased from Sasol GmbH (Witten, Germany). Poloxamer F68 was bought from BASF SE (Ludwigshafen, Germany).
Ellman's Reagent, 5,5'-dithiobis(2-nitrobenzoate) (DTNB) was purchased from Molekula (Gillingham, UK). Tris buffer and Tween 80 were bought from Fisher. 
Suppository preformulation and manufacture
To allow for wastage, the weight of eight suppositories was calculated for a six-form mould. The calibration value was calculated for each mould, and the displacement value was calculated for each drug. The bases were weighed accurately on a Mettler AE50 analytical balance, along with the active. The bases were heated and blended together, before addition of either cysteamine or phenylalanine conjugate. This mix was then thoroughly stirred and the resultant liquid poured into a mould and allowed to cool. The tops were then trimmed with a spatula, and the final forms removed from the mould, bottled and labeled (BP, 2005) . The surfactant Tween 80 was used in some formulations to ensure the fatty bases were sampled accurately from the dissolution medium.
Lipophilic bases, hydrophilic bases and blends of different PEG grades were examined for optimum characteristics. As 10 mg kg -1 was used for previous rectal delivery of cysteamine, 60mg was used as a nominal value (17) . Until further tests are carried out in vivo, the correct dose cannot be determined.
Suppository hardness was tested on an Erweka TBH28 hardness tester (Heusenstamm, Germany). A hardness value of at least 1.8-2kg is considered acceptable for unmedicated suppositories (18) . If the inert suppository blend produced unsatisfactory results beyond this range, no further testing was performed. The suppositories with the best characteristics, based on hardness tests and appearance were selected for further testing.
Dissolution studies
Dissolution tests were performed in a six-chambered Sotax CH-4123 dissolution bath (Basel, Switzerland). The dissolution test method followed the standard BP test for suppositories: one suppository in a stainless-steel basket, rotating at 100 rpm in a 1L beaker containing medium at 37°C, sampling at 5 minute intervals for 1 hour (BP 2005 Edition).
The dissolution medium was altered depending on the active used. The release was measured by UV spectroscopy. The samples were returned to the bath after analysis.
Suppositories containing the phenylalanine conjugate were initially tested in distilled water, using UV absorbance at 256 nm corresponding to the λmax. 
Active dispersion studies
In a suppository, there is a possibility that the tip might contain more drug than the rest of the form due to gravitational settling (18) . To ensure uniform drug loading, three separate areas of the suppository were sampled and compared using a DSC Q100 Differential Scanning Calorimeter (TA instruments Delaware, USA) and the experiment carried out in triplicate. Coupled with this, DSC studies of suppositories were carried out, to determine the thermal characteristics of each suppository blend.
Stability tests
Stability studies were conducted over a 12-month period. Upon manufacture (T0), the suppositories were stored under three different environmental conditions in order to determine their stability; a refrigerator at 4C and 8 %RH (Relative Humidity), a store containing a desiccator with saturated sodium hydrogen sulphate solution at 20°C and 52 %RH (20) , and an Environmental Test Chamber (Copely, Nottingham, England) set at 30C and 75 %RH (21) . These conditions were selected to simulate cold storage, typical home storage and accelerated testing. As the suppositories had low melting points, it was decided to reduce the commonly used accelerated temperature from 37C to 30C. The temperature in each of the storage areas was monitored daily. DSC and IR spectroscopy were undertaken every week for one month, every month for 3 months, and subsequently every 3 months for 12 months, and compared with the T0 results (21) . IR Spectroscopy, was undertaken using a Nicolet IS10 IR from Thermo Scientific (Fisher, UK) with a Smart iTR attachment and a diamond HATR (horizontal attenuated total reflectance). Thiol groups absorb at a wavenumber of 2600 to 2550cm -1 , while disulphides absorb between 620 and 600cm -1 (22) . These measurements were used as the basis for the comparisons made between samples.
Samples of uniformly less than 10mg were placed in a standard aluminium pan for DSC analysis. The DSC was set to a heat-cool-heat cycle, where the sample was equilibrated at 0°C, then heated to 100°C at 10°C per minute, equilibrated at 100°C, then cooled at 10°C per minute to 0°C, before being heated again to 100°C at 10°C per minute.
Results and discussion
The final three suppositories selected for further characterisation were blend "A" (40% PEG 8000, 60% PEG 600), blend "B" (40% PEG 14000, 60% PEG 600) and blend "C" (PEG 1500) (table 1). There is a large variation in release onset in forms A, B and C, which is illustrated by large standard deviation values. T100 for PEG blends A, B and C were observed at 20, 45 and 60 minutes respectively (n = 5-9). PEG blend C released the phenylalanine conjugate more slowly than PEG blends A and B. This may be due to the greater hardness of blend C (table 2). The fatty bases Witepsol and Gelucire produced a more homogenous blend and melted instantly (data not shown), whereas the PEG bases produced a more prolonged dissolution profile and dissolved more slowly over time (figure 2). It was decided to continue studies using PEG bases only, as they produced a more prolonged release of 20-60 minutes compared to 2 minutes for Witepsol and Gelucire. This slower dissolution of the PEGs allows the drug to be in contact with the rectum for longer where it is more likely to be absorbed into the body. A sudden melt over 2 minutes would increase the chances of the drug being lost through expulsion. All three PEG blends containing cysteamine hydrochloride as the active displayed more reproducible profiles than dissolution using the phenylalanine conjugate. The PEG bases should dissolve at the same rate in every replicate, and this may have been due to nonuniform drug loading of the phenylalanine conjugate. The phenylalanine conjugate was developed initially to allow release from the dosage forms, to be monitored spectrophotometrically. It should be noted that cysteamine hydrochloride is a difficult drug to formulate. At room temperature it undergoes oxidation to a disulphide form, cystamine, which itself has been shown to deplete cells of cystine but which is not licensed for use (5, 23, 24) . Cysteamine is also extremely hygroscopic and deliquescent. However, the introduction of DTNB as a quantitative reagent allowed measurement of cysteamine directly. A summary of the release times obtained is shown in table 3. The data produced using Ellman's reagent demonstrated excellent reproducibility (average standard error of the mean for PEG Blend: A -0.39, B -0.58, C -0.14). 
Active dispersion studies
To ensure cysteamine hydrochloride was evenly dispersed throughout the suppository, samples were taken from three separate portions of the suppository and analysed using DSC (figure 4). There was minimal difference between the tip, edge and middle sections of the suppository suggesting a uniform dispersion of active within the PEG suppository. 
Stability tests
The temperature and relative humidity in each of the three storage chambers were monitored continuously throughout a 12 month period. The average results obtained are shown in table 4. Such changes are not evident. Infrared spectroscopy utilizes a set of unique peaks on a spectrum which can be used for identifying a compound. Each of the suppository samples was determined by IR spectroscopy and added to a compound library. A percentage match was then performed on each sample (table 6 ).
The oxidation of cysteamine to cystamine was the basis of comparisons made between samples. This reaction produces a peak in the region of disulphide bond stretch, i.e. 620-600 cm -1 , and allows a simple identification of sample degradation.
Each suppository was analysed over time using the IR spectrometer, and compared to the suppositories at time zero. The results are shown in table 6 (selected examples only).
The stability tests using IR analysis demonstrated that PEG blend C was the most stable in all conditions, with minimal changes over six months at room temperature and accelerated tests, and up to twelve months stability when stored at 4° C. PEG blend B shows evidence of stability over twelve months at room temperature. PEG blend A shows evidence of degradation when subjected to a range of storage conditions, and therefore is unsuitable for the rectal delivery of cysteamine. 
Correlation between DSC plots and IR percentage match results
The IR percentage match data support the DSC plots. This is evidence of correlation between the two methods and allows a more conclusive result to be produced. For example, PEG blend C stored at 21°C displayed a 98.94% match at 6 months (table 6) .
These stability test results support the hardness testing, and indicate that PEG Blend C was the most stable formulation over a 12-month period, and indicate that PEG Blend C was the most stable formulation over a 12-month period. The suppositories stored at 4°C were generally more stable than those stored at higher temperatures, although PEG blend C displays long term stability even at room temperature. PEG blend B suppositories were stable over time at room temperature. PEG blend A suppositories displayed long term instability under all storage conditions. PEG blend C displays ideal stability over time in a range of storage conditions and is proposed as the optimal formulation in this study.
Conclusions
Liquid gel suppositories containing cysteamine have previously been investigated for the treatment of cystinosis (17) . However, due to the osmotic nature of the suppository vehicle, the doses were rapidly expelled and cysteamine blood plasma concentrations were insufficient to produce a reduction in mean leukocyte cystine concentration. In this project, the suppository bases Witepsol, Gelucire and PEG were investigated for their suitability as vehicles for the incorporation of cysteamine hydrochloride and a phenylalanine-cystamine conjugate. Melting point, hardness, stability and appearance were analysed, and the three suppository bases with the most suitable characteristics were chosen for further study. PEG blends A, B and C were made and characterised. Blend C displayed good qualities (i.e.
complete, reproducible release after 30 minutes, stability over 12 months at 4°C/8% RH) required for the delivery of cysteamine hydrochloride to the rectum. DSC analysis indicated that cysteamine hydrochloride was dispersed uniformly in the suppositories.
Dissolution studies using the phenylalanine-cystamine conjugate revealed 20-60 minute release, while cysteamine hydrochloride as the active component demonstrated [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] minute release on average. The stability tests indicate that 4°C/8% RH provided the ideal storage conditions over a 12-month period. Formulation C was the most stable over time, while blend A was the least stable form, and even when stored in the refrigerator was subject to degradation. There was also evidence of an incompatibility between cysteamine hydrochloride and PEG Blends A and B, and this may be a combination of physical ageing of the PEG and syneresis of cysteamine (26) (27) (28) (29) . There was evidence that crystal ripening over time is forcing the expulsion of the cysteamine hydrochloride to the outside surfaces of the suppository. The highly deliquescent cysteamine then quickly dissolves in environmental moisture, forming droplets of liquid on the surface of the suppositories. For these reasons, PEG blends A and B would not be suitable for the rectal delivery of cysteamine. Analysis indicates that PEG blend C would be an ideal suppository base for the delivery of cysteamine hydrochloride.
These tests demonstrate that cysteamine hydrochloride can be formulated as a suppository, and that the bases can tolerate varying amounts of drug loading. This will be of particular benefit when treating cystinosis during infancy, and should allow a significant reduction in side effects, improving compliance and morbidity. In addition, suppositories may help to eliminate the overnight treatment break which is difficult to overcome with the oral capsules. Future work with the suppositories will involve the development of in-situ gelling forms, and should include in-vivo testing or an in-vitro in-vivo correlation (IVIVC)
to investigate the potential benefits these forms may have compared to the current oral treatment.
